Are there specific blood biomarkers that predict major depression outcomes in UK Biobank?
Researchers are looking for blood biomarkers—measurable substances in the blood—that could help predict how major depression will respond to treatment. The UK Biobank is a large study that includes data on hundreds of thousands of people, making it a valuable resource for this kind of research. However, so far, no single blood test has been proven to reliably predict depression outcomes in this or other large studies. The search continues, but the evidence is still too uncertain for clinical use.
What the research says
A 2024 analysis of UK Biobank data examined how various factors influence 29 common blood biomarkers in psychiatric research. It found that technical, demographic, and behavioral factors—such as age, sex, body mass index (BMI), and smoking—strongly affect these markers. For example, inflammatory markers were influenced by BMI and smoking, and many biomarkers showed daily or seasonal variations. When the researchers looked at associations between these biomarkers and major depression, adjusting for these factors weakened or eliminated many of the links 3. This suggests that without careful control, apparent biomarker associations may be misleading.
Other studies have explored different types of blood biomarkers for depression, but not specifically in UK Biobank. A 2018 review noted that despite many candidate biomarkers—including genetic, epigenetic, and inflammatory markers—none have yet shown enough specificity, sensitivity, and reproducibility to be used in clinical practice 6. Similarly, a 2015 study identified blood transcript (gene expression) markers that could distinguish people with major depression from healthy controls, but these findings need further validation in larger, diverse populations 8.
MicroRNAs, which are small molecules that regulate gene expression, have also been studied. A 2016 study found that levels of let-7b and let-7c microRNAs were lower in people with treatment-resistant depression compared to controls, and these levels changed with treatments like electroconvulsive therapy 7. However, this was a small study and not based on UK Biobank data.
Polygenic risk scores (PRS), which combine many genetic variants, have shown some promise in UK Biobank for distinguishing between depression and anxiety, but they are not blood biomarkers per se and are not yet ready for clinical prediction 5. Overall, while research is active, no blood biomarker has been validated to predict major depression outcomes in UK Biobank or elsewhere.
What to ask your doctor
- What are the current limitations of blood biomarker tests for depression?
- Are there any ongoing studies or clinical trials using biomarkers to guide depression treatment?
- How do factors like age, weight, and smoking affect the interpretation of blood tests in depression?
- Should I consider genetic testing or other personalized approaches for my depression treatment?
- What are the most reliable ways to monitor my depression treatment response currently?
This question is drawn from common patient questions about Psychiatry and answered using cited medical research. We do not provide individualized advice.